TTechnology Read More BCLXL blockade rewires cell fate to overcome PARP inhibitor resistance in ovarian cancerSeptember 21, 2026 Kaufman, B. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin.…